Pressmeddelande

Medivir’s CEO: “There is an obvious need for fostrox”

Cision Publicerad: 11 Nov 09:55

Medivir has gone through an eventful period, marked by the presentation of clinical results at ESMO and a new collaboration agreement with pharmaceutical giant Eisai. The next target is a randomized phase IIb study to enable breakthrough therapy designation and accelerated approval process. CEO Jens Lindberg notes that these recent developments have strengthened fostrox’s potential to become the first approved treatment for second-line liver cancer.

Read the article at biostock.se:

https://www.biostock.se/en/2024/11/medivirs-ceo-there-is-an-obvious-need-for-fostrox/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Medivir

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!